Feb 18, 2003
Abbott Laboratories on Monday said clinical trials of J695, a human
monoclonal antibody that neutralises interleukin-12, are about to start
in multiple sclerosis in addition to the previously announced trials in
rheumatoid arthritis and Crohn's disease.
© Copyright 2003, Reuters Health